Search
Sanofi Finalizes $9+ Billion Acquisition of Biopharmaceutical Giant Blueprint Medicines
2025-07-18 /
Read about 0 minute
Author：小编
On July 18, the French pharmaceutical giant Sanofi announced the successful completion of its acquisition of the U.S.-based biopharmaceutical company Blueprint Medicines, in a deal valued at approximately $9.1 billion. This acquisition encompasses Blueprint's flagship product, Ayvakit/Ayvakyt (avapritinib), a drug approved in both the United States and the European Union for the treatment of rare immune diseases. As per the terms disclosed in June, Sanofi acquired all outstanding shares of Blueprint at a cash price of $129 per share. The transaction underscores Sanofi's commitment to enhancing its footprint in the realm of rare diseases and immunology.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
